Tab 1

London is the capital city of England.

It is the most populous city in the United Kingdom, with a metropolitan area of over 13 million inhabitants.

Recent update : CORBEVAX is now available for 12 years and above on COWIN as primary vaccination.
Key attributes
Developed through well established platform

Protein subunit vaccine containing receptor binding domain (RBD) of SARS-CoV-2 virus produced through well-established platform (which is used for the production of vaccines like Hepatitis B).

Enhances both antibody and cellular immune response

Contains CpG1018 and aluminium hydroxide as adjuvants which enhances both antibody and cellular immune responses against SARS-CoV-2 virus.

Clinical trial demonstrates high safety and immunogenicity

4 Clinical trials involving 4392 volunteer subjects of age group 5 to 80 years from >35 study centres across India to demonstrate the safety and immunogenicity.

Significantly higher neutralizing antibody

Significantly higher neutralizing antibody titres compared to Covishield for both Wuhan and Delta variants. Robust antibody and cellular immune response.

High persistence of neutralizing antibody titres

Long term follow-up (≥ 6months) data shows high persistence of neutralizing antibody titres.

Neutralizing antibodies demonstrated against Delta, Beta and Omicron variants

Adverse events 50% lesser than comparator vaccine

Excellent safety profile; No severe grades or serious adverse events. No adverse events of special interest on long term monitoring. Mild to moderate adverse events were almost 50% less than the comparator Covid-19 vaccine.

Highly effective against symptomatic infection and severe diseases

Neutralizing antibody titers and clinical trial experience indicates high vaccine effectiveness in preventing symptomatic infection and severe disease; >90% vaccine effectiveness against Wuhan variant and >80% vaccine effectiveness against Delta variant based on neutralizing antibodies correlates of protection from Covid-19 vaccine trial analysis.

Developed through well established platform Protein subunit vaccine containing receptor binding domain (RBD) of SARS-CoV-2 virus produced through well-established platform (which is used for the production of vaccines like Hepatitis B).
Enhances both antibody and cellular immune response Contains CpG1018 and aluminium hydroxide as adjuvants which enhances both antibody and cellular immune responses against SARS-CoV-2 virus.
Clinical trial demonstrates high safety and immunogenicity 4 Clinical trials involving 4392 volunteer subjects of age group 5 to 80 years from >35 study centres across India to demonstrate the safety and immunogenicity.
Significantly higher neutralizing antibody Significantly higher neutralizing antibody titres compared to Covishield for both Wuhan and Delta variants. Robust antibody and cellular immune response.
High persistence of neutralizing antibody titres Long term follow-up (≥ 6months) data shows high persistence of neutralizing antibody titres.
Effective against various strains of SARS-CoV-2 virus Neutralizing antibodies demonstrated against Delta, Beta and Omicron variants
Adverse events 50% lesser than comparator vaccine Excellent safety profile; No severe grades or serious adverse events. No adverse events of special interest on long term monitoring. Mild to moderate adverse events were almost 50% less than the comparator Covid-19 vaccine.
Highly effective against symptomatic infection and severe diseases Neutralizing antibody titers and clinical trial experience indicates high vaccine effectiveness in preventing symptomatic infection and severe disease; >90% vaccine effectiveness against Wuhan variant and >80% vaccine effectiveness against Delta variant based on neutralizing antibodies correlates of protection from Covid-19 vaccine trial analysis.
Important Information on CORBEVAX
News
Over 2.3 crore children in 12-14 age group received covid jab

New Delhi: More than 2.32 children in the age group of 12-14 years have received covid-19 vaccine doses so far, taking the total vaccination

Read More...

Most Affordable": Biological E Chief On Kids' Vaccine Corbevax

New Delhi: Mahima Datla, the MD of Biological E -- whose vaccine Corbevax was launched today for 12 to 14-year-olds in the country

Read More...

Biological E aims to produce 100 mn doses/month of Corbevax

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million

Read More...

Corbevax: Biological E to produce 100 million doses per month

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million

Read More...

Biological E To Produce 75 Million Doses Per Month Of Corbevax To Meet 30 Crore Demand

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million

Read More...

Biological E's Covid vaccine Corbevax receives emergency use nod for children aged 12-18 yrs

The Drugs Controller General of India (DCGI) on Monday gave an emergency use nod to Hyderabad-based pharmaceutical company Biological E's

Read More...

Over 2.3 crore children in 12-14 age group received covid jab

New Delhi: More than 2.32 children in the age group of 12-14 years have received covid-19 vaccine doses so far, taking the total vaccination

Read More...

Most Affordable": Biological E Chief On Kids' Vaccine Corbevax

New Delhi: Mahima Datla, the MD of Biological E -- whose vaccine Corbevax was launched today for 12 to 14-year-olds in the country

Read More...

Biological E aims to produce 100 mn doses/month of Corbevax

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million

Read More...

Corbevax: Biological E to produce 100 million doses per month

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million

Read More...

Biological E To Produce 75 Million Doses Per Month Of Corbevax To Meet 30 Crore Demand

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million

Read More...

Biological E's Covid vaccine Corbevax receives emergency use nod for children aged 12-18 yrs

The Drugs Controller General of India (DCGI) on Monday gave an emergency use nod to Hyderabad-based pharmaceutical company Biological E's

Read More...

Videos
CORBEVAX - India's 1st indigenous protein subunit vaccine
India's 'Vaccine Woman' On Corbevax Rolled Out For Children
Ms. Mahima Datla in a conversation with Rajya Sabha TV
CORBEVAX - India's 1st indigenous protein subunit vaccine
India's 'Vaccine Woman' On Corbevax Rolled Out For Children
Ms. Mahima Datla in a conversation with Rajya Sabha TV
Dr. Vikram Paradkar in an interview with ABP news
Power to Protect
.
×

The information on this website is intended for use only by residents of the United States of America. The product information on this site is provided for general information purposes only and is not intended to be a substitute for the actual approved product information. This information is neither medical advice nor a substitute for discussions with a qualified medical professional. The products listed are available only through prescription by a qualified medical professional. BE Pharmaceuticals Inc. and its affiliates shall not be responsible for the reliance on or use of any information contained herein. The reader understands and agrees to the foregoing.

I AgreeI Decline

Contact Us

×
Mahima Datla